使ublituximab:ULTIMATE III

Bruce A C Cree1, Edward Fox2, Hans-Peter Hartung3,4,5

  • 1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco.

JAMA neurology
|February 16, 2026
PubMed
概括

在复发性多发性硬化症 (RMS) 中,长期使用ublituximab治疗证明了持续的疗效,在五年内显著降低了年度复发率和残疾进展. 早期启动这种高效疗法被证实可以提供持久的临床益处.

相关概念视频

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...